Skip to main content

Advertisement

SpringerLink
Log in

Acute Hepatitis C: Management in the Rapidly Evolving World of HCV

  • Liver (B Bacon, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The acute phase of hepatitis C (HCV) infection is typically defined as the initial 6 months following exposure to the virus; however, in some individuals, the acute phase of the infection can last much longer (Orland et al. Hepatology 33:321–27, 2001). Although some patients have symptoms of acute hepatitis, most infected individuals are entirely asymptomatic. As a result, many patients are unaware of the infection until it progresses to chronic infection, and may not develop symptoms until decades later with the onset of decompensated cirrhosis or hepatocellular carcinoma (HCC). A substantial proportion (20–40 %) of infected patients clear the virus during the acute phase. Interferon-based treatment is also much more likely to be successful in the acute phase of infection but is relatively poorly tolerated. Therefore, recognition of acute HCV infection is critical to prioritize those patients who do not spontaneously clear the infection for immediate therapy. However, the promise of highly effective well-tolerated all-oral therapies in development may alter the management approach. This review will focus on the epidemiology, natural history, diagnosis, and treatment of acute HCV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.

    Article  PubMed  Google Scholar 

  2. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012;19:560–7.

    Article  CAS  PubMed  Google Scholar 

  3. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355:887–91.

    Article  CAS  PubMed  Google Scholar 

  4. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA. 2010;107:14757–62.

    Article  PubMed  Google Scholar 

  5. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61–80.

    Article  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. MMWR. 2012;61:545–9.

    Google Scholar 

  7. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M, et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo. Egypt Gut. 2010;59:1554–60.

    Article  CAS  Google Scholar 

  8. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS ONE. 2009;4:e8467.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. WJG. 2009;15:5647–53.

    Article  PubMed  Google Scholar 

  10. Liu F, Chen K, He Z, Ning T, Pan Y, Cai H, et al. Hepatitis C seroprevalence and associated risk factors, Anyang, China. Emerg Infect Dis. 2009;15:1819–22.

    Article  PubMed  Google Scholar 

  11. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148–62.

    Article  PubMed  Google Scholar 

  12. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38:864–70.

    Article  CAS  PubMed  Google Scholar 

  13. Naoumov NV. Hepatitis C, virus infection in Eastern Europe. J Hepatol. 1999;31 Suppl 1:84–7.

    Article  PubMed  Google Scholar 

  14. Kalinina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, et al. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol. 2001;65:517–24.

    Article  CAS  PubMed  Google Scholar 

  15. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Lvov DK, Samokhvalov EI, Tsuda F, Selivanov NA, Okamoto H, Stakhanova VM, et al. Prevalence of hepatitis C virus and distribution of its genotypes in Northern Eurasia. Arch Virol. 1996;141:1613–22.

    Article  CAS  PubMed  Google Scholar 

  17. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.

    Article  PubMed  Google Scholar 

  18. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo C-G, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1–32.

    PubMed  Google Scholar 

  19. phac-aspc.gc.ca [Internet]. [cited 2013 Sep 28]. Available from: http://www.phac-aspc.gc.ca.

  20. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171:242–8.

    Article  PubMed  Google Scholar 

  21. Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther (Lond). 2012;17:1423–9.

    Article  Google Scholar 

  22. Fischer GE, Schaefer MK, Labus BJ, Sands L, Rowley P, Azzam IA, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis. 2010;51:267–73.

    Article  PubMed  Google Scholar 

  23. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001;33:321–7.

    Article  CAS  PubMed  Google Scholar 

  24. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325:98–104.

    Article  CAS  PubMed  Google Scholar 

  25. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994–1002.

    Article  PubMed  Google Scholar 

  26. Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, et al. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42:86–92.

    Article  CAS  PubMed  Google Scholar 

  27. Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine. 2012;59:460–6.

    Article  CAS  PubMed  Google Scholar 

  28. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395–406.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Seeff LB. Natural history of hepatitis C. 1997. p. 21S–8S.

  30. Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther. 2011;33:559–65.

    Article  CAS  PubMed  Google Scholar 

  31. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401–12.

    Article  PubMed  Google Scholar 

  32. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. YGAST. 2003;125:80–8.

    Google Scholar 

  33. Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med. 1996;335:631–4.

    Article  CAS  PubMed  Google Scholar 

  34. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol. 2012;57:1349–60.

    Article  PubMed  Google Scholar 

  35. McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49:1051–60.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat. 1996;3:75–8.

    Article  CAS  PubMed  Google Scholar 

  37. Fanning L, Kenny-Walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, et al. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology. 2000;31:225–9.

    Article  CAS  PubMed  Google Scholar 

  38. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology. 1998;28:1702–6.

    Article  CAS  PubMed  Google Scholar 

  39. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.

    Article  CAS  PubMed  Google Scholar 

  40. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908–14.

    Article  CAS  PubMed  Google Scholar 

  41. Grebely J, Page K, Sacks-Davis R, Schim van der Loeff M, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection. Hepatology. 2014;59(1):109–20. This study uses a large international cohort of patients with acute HCV to identify predictors of spontaneous clearance, showing that IL28B, HCV genotype and gender were predictive factors.

  42. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474–82.

    Article  PubMed  Google Scholar 

  43. Rao H-Y, Sun D-G, Jiang D, Yang R-F, Guo F, Wang J-H, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19:173–81.

    Article  PubMed  Google Scholar 

  44. Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673–81.

    Article  CAS  PubMed  Google Scholar 

  45. Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol. 2013;59:221–8.

    Article  PubMed  Google Scholar 

  46. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59(5):972–7. This study uses a cohort of 136 patients with acute HCV to identify predictors of spontaneous clearance and then to develop a score to predict spontaneous clearance. Once validated, this could be a useful tool for practitioners.

    Article  PubMed  Google Scholar 

  48. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586–92. 1592.e1.

    Article  CAS  PubMed  Google Scholar 

  49. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology. 2013;57:2124–34. IP-10 levels may provide an additional means of risk stratification. Patients with high IP-10 levels were shown to have a lower likelihood of spontaneous clearance, allowing for early identification of patients who merit treatment.

    Article  CAS  PubMed  Google Scholar 

  51. Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, et al. IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients. Antivir Ther (Lond). 2011;16:1309–16.

    Article  CAS  Google Scholar 

  52. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology. 2013;144:414–425.e7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. YGAST. 2006;131:1887–98.

    Google Scholar 

  54. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis 2014;209(3):350–4.

    Google Scholar 

  55. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky J-M, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194:895–903.

    Article  CAS  PubMed  Google Scholar 

  57. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky J-M, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44:1617–25.

    Article  CAS  PubMed  Google Scholar 

  58. Dill MT, Makowska Z, Duong FHT, Merkofer F, Filipowicz M, Baumert TF, et al. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology. 2012;143:777–86.e1–6.

    Article  CAS  PubMed  Google Scholar 

  59. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142:978–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Feld JJ, Grebely J, Matthews GV, Applegate T, Hellard M, Sherker A, et al. Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. PLoS One. 2013;8(11):e80003. doi:10.1371/journal.pone.0080003.

  61. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology. 2010;51:1168–75.

    Article  CAS  PubMed  Google Scholar 

  62. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872–4.

    Article  CAS  PubMed  Google Scholar 

  63. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141:1231–9. 1239.e1–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Knapp S, Warshow U, Ho KMA, Hegazy D, Little A-M, Fowell A, et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology. 2011;141:320–5. 325.e1–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98:706–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 1997;25:449–58.

    Article  CAS  PubMed  Google Scholar 

  67. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578–82.

    Article  CAS  PubMed  Google Scholar 

  68. Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol. 1998;28:1–7.

    Article  CAS  PubMed  Google Scholar 

  69. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol. 1998;29:207–13.

    Article  CAS  PubMed  Google Scholar 

  70. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol. 1999;73:2938–46.

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000;288:339–44.

    Article  CAS  PubMed  Google Scholar 

  72. Chen S, Wang Y-M. Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus. WJG. 2005;11:2874–84.

    CAS  PubMed  Google Scholar 

  73. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–7.

    Article  CAS  PubMed  Google Scholar 

  74. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39:1213–9.

    Article  CAS  PubMed  Google Scholar 

  75. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–33.

    Article  CAS  PubMed  Google Scholar 

  76. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–6.

    Article  CAS  PubMed  Google Scholar 

  77. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat. 2007;14:116–21.

    Article  CAS  PubMed  Google Scholar 

  78. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17:201–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  79. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721–31.

    Article  CAS  PubMed  Google Scholar 

  80. Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS. 2012;26:1653–61.

    Article  CAS  PubMed  Google Scholar 

  81. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.

    Article  Google Scholar 

  82. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Tawil Al A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632–8.

    Article  CAS  PubMed  Google Scholar 

  83. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923–31.

    Article  CAS  PubMed  Google Scholar 

  84. Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55:76–85.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141–7.

    Article  PubMed  Google Scholar 

  86. Martin TCS, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS. 2013;27(16):2551–7.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Suraj A. Sharma has no conflicts. Jordan J. Feld has received grants from BI and Gilead and payment for presentations from Abbvie, Roche, Gilead ad Vertex.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Toronto Center for Liver Disease, Sandra Rotman Centre for Global Health, University Health Network, University of Toronto, 6B-Fell Pavilion, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada

    Suraj A. Sharma & Jordan J. Feld

Authors
  1. Suraj A. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan J. Feld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jordan J. Feld.

Additional information

This article is part of the Topical Collection on Liver

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, S.A., Feld, J.J. Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. Curr Gastroenterol Rep 16, 371 (2014). https://doi.org/10.1007/s11894-014-0371-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-014-0371-7

Keywords

Search

Navigation